Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine
Retrieved on:
Tuesday, October 17, 2023
Science, Other Science, Biotechnology, Research, Health, Genetics, Clinical Trials, Other Health, Investment, Multimedia, DHR, Danaher Corporation, NYSE, ICH, Cas12a, Biology, Static pressure, Genome, Therapy, Integrated DNA Technologies, Temperature, ISO, CGMP, RUO, Humidity, ISO 8, Ultra, Documentation, Oligonucleotide, IDT, Drug discovery, Integration, RNA, Genomics, Danaher, HDR, Fine chemical, Medical device, CRISPR
Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE:DHR), today announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa.
Key Points:
- Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE:DHR), today announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa.
- These new capabilities and offerings will be supported with comprehensive documentation and testing, a support team, and regulatory guidance to help accelerate researchers’ path to the clinic.
- As a pioneer in genome editing, IDT’s continued investments will enable customers to rapidly move from clinical development to commercialization.
- Mortenson Company, a team led by OPN Architects and Barr Engineering Co. on the facility design and construction of its cGMP facility.